Peter Ellmark

1 – 10 of 42

show: 10
|
sort: year (new to old)

News feed Embed this list Save this search Mark all Export

Cancel

Embed this list

copy and paste the html snippet below into your own page:

<iframe src="https://lup.lub.lu.se/search/person/immt-pel?embed=1&amp;hide_pagination=1&amp;hide_info=1&amp;hide_options=1"
  width="100%"
  height="400"
  allowtransparency="true"
  frameborder="0">
</iframe>

« previous
1
2
3
4
5
next »

2022
Mark Transcriptional profiling demonstrates altered characteristics of CD8 + cytotoxic T-cells and regulatory T-cells in TP53-mutated acute myeloid leukemia
Abolhalaj, Milad ^LU ; Sincic, Viktor ^LU ; Lilljebjörn, Henrik ^LU ; Sandén, Carl ^LU ; Aab, Alar ^LU ; Hägerbrand, Karin ^LU ; Ellmark, Peter ^LU ; Borrebaeck, Carl ^LU ; Fioretos, Thoas ^LU and Lundberg, Kristina ^LU (2022) In Cancer Medicine
- Contribution to journal › Article
2021
Mark CD137 (4-1BB) costimulation of CD8⁺ T cells is more potent when provided in cis than in trans with respect to CD3-TCR stimulation
Otano, Itziar ; Azpilikueta, Arantza ; Glez-Vaz, Javier ; Alvarez, Maite ; Medina-Echeverz, José ; Cortés-Domínguez, Ivan ; Ortiz-de-Solorzano, Carlos ; Ellmark, Peter ^LU ; Fritzell, Sara ^LU and Hernandez-Hoyos, Gabriela , et al. (2021) In Nature Communications 12(1).
- Contribution to journal › Article
Mark Rationale and clinical development of CD40 agonistic antibodies for cancer immunotherapy
Enell Smith, Karin ^LU ; Deronic, Adnan ^LU ; Hägerbrand, Karin ^LU ; Norlén, Per ^LU and Ellmark, Peter ^LU (2021) In Expert Opinion on Biological Therapy 21(12). p.1635-1646
- Contribution to journal › Scientific review
Mark The human anti-CD40 agonist antibody mitazalimab (ADC-1013; JNJ-64457107) activates antigen-presenting cells, improves expansion of antigen-specific T cells, and enhances anti-tumor efficacy of a model cancer vaccine in vivo
Deronic, Adnan ^LU ; Nilsson, Anneli ; Thagesson, Mia ; Werchau, Doreen ; Enell Smith, Karin ^LU and Ellmark, Peter ^LU (2021) In Cancer Immunology, Immunotherapy 70(12). p.3629-3642
- Contribution to journal › Article
2020
Mark Transcriptomic profiling of T-cell populations in non-muscle invasive and muscle invasive bladder cancer.
Sincic, Viktor ^LU ; Abolhalaj, Milad ^LU ; Lilljebjörn, Henrik ^LU ; Aab, Alar ^LU ; Hägerbrand, Karin ^LU ; Ellmark, Peter ^LU ; Fioretos, Thoas ^LU ; Borrebaeck, Carl ^LU ; Liedberg, Fredrik ^LU and Lundberg, Kristina ^LU (2020) The Society for Immunotherapy of Cancer's (SITC) 35th annual meeting In Journal for ImmunoTherapy of Cancer 8(Suppl. 3).
- Contribution to journal › Published meeting abstract
2018
Mark Administration of low-dose combination anti-CTLA4, anti-CD137, and anti-OX40 into murine tumor or proximal to the tumor draining lymph node induces systemic tumor regression
Hebb, Jonathan P.O. ; Mosley, Adriane R. ; Vences-Catalán, Felipe ; Rajasekaran, Narendiran ; Rosén, Anna ; Ellmark, Peter ^LU and Felsher, Dean W. (2018) In Cancer Immunology, Immunotherapy 67(1). p.47-60
- Contribution to journal › Article
2017
Mark Tumor-directed immunotherapy can generate tumor-specific T cell responses through localized co-stimulation
Ellmark, Peter ^LU ; Mangsbo, Sara M. ; Furebring, Christina ^LU ; Norlén, Per ^LU and Tötterman, Thomas H. (2017) In Cancer Immunology and Immunotherapy 66(1). p.1-7
- Contribution to journal › Article
Mark Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer
van Hooren, Luuk ; Sandin, Linda C ; Moskalev, Igor ; Ellmark, Peter ^LU ; Dimberg, Anna ; Black, Peter ; Tötterman, Thomas H and Mangsbo, Sara M (2017) In European Journal of Immunology 47(2). p.385-393
- Contribution to journal › Article
2016
Mark Selective FcγR engagement by human agonistic anti-CD40 antibodies
Ellmark, Peter ^LU ; Mangsbo, Sara M. and Lindstedt, Malin ^LU (2016) In Translational Cancer Research 5. p.839-841
- Contribution to journal › Debate/Note/Editorial
2015
Mark Kick-starting the cancer-immunity cycle by targeting CD40
Ellmark, Peter ^LU ; Mangsbo, S. M. ; Furebring, C. ; Totterman, T. H. and Norlen, P. (2015) In OncoImmunology 4(7). p.1011484-1011484
- Contribution to journal › Debate/Note/Editorial

« previous
1
2
3
4
5
next »